Home » HELSINN AND PFIZER LABORATORIES (PTY) LTD SIGN A LICENSE AGREEMENT FOR THE MARKETING OF ALOXI IN SOUTH AFRICA
HELSINN AND PFIZER LABORATORIES (PTY) LTD SIGN A LICENSE AGREEMENT FOR THE MARKETING OF ALOXI IN SOUTH AFRICA
Helsinn Healthcare SA, and Pfizer Laboratories (Pty) Ltd, announce the signing of an agreement granting Pfizer in South Africa, the exclusive license and distribution rights of Aloxi (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by chemotherapy. Aloxi will be launched in South Africa under the trade name Onicit.
PR Newswire (http://www.prnewswire.co.uk/cgi/news/release?id=165888)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May